Open Access
Regen Med Res
Volume 7, 2019
Article Number 2
Number of page(s) 9
Published online 10 December 2019
  1. Ahmad RS, Barritault D (2018), ReGeneraTing Agents (RGTA(R)) are a new option to improve amputation outcomes in the recovery of severe hand injuries, Clin Case Rep 6, 2061–2069. [PubMed] [Google Scholar]
  2. Albert S (2002), Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 19, 483–491. [Google Scholar]
  3. ATIH 2017; Available from: [Google Scholar]
  4. Barbier-Chassefiere V, Garcia‐Filipe S, Yue XL, Kerros ME, Petit E, Kern P, Saffar JL, Papy‐Garcia D, Caruelle JP, Barritault D (2009), Matrix therapy in regenerative medicine, a new approach to chronic wound healing, J Biomed Mater Res A 90, 641–647. [CrossRef] [PubMed] [Google Scholar]
  5. Bircher AJ, Fluckiger R, Buchner SA (1990), Eczematous infiltrated plaques to subcutaneous heparin: a type IV allergic reaction. Br J Dermatol 123, 507–514. [CrossRef] [PubMed] [Google Scholar]
  6. Chebbi CK, Kichenin K, Amar N, Nourry H, Warnet JM, Barritault D, Baudouin C (2008), Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy. J Fr Ophtalmol 31, 465–471. [CrossRef] [PubMed] [Google Scholar]
  7. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J (1999), A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J 13, 761–766. [CrossRef] [PubMed] [Google Scholar]
  8. Dillingham TR, Pezzin LE, Shore AD (2005), Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. Arch Phys Med Rehabil 86, 480–486. [CrossRef] [PubMed] [Google Scholar]
  9. Franklin H, Rajan M, Tseng CL, Pogach L, Sinha A, Mph M (2014), Cost of lower-limb amputation in U.S. veterans with diabetes using health services data in fiscal years 2004 and 2010. J Rehabil Res Dev 51, 1325–1330. [CrossRef] [PubMed] [Google Scholar]
  10. Gupta U, Verma M (2013), Placebo in clinical trials. Perspect Clin Res 4, 49–52. [CrossRef] [PubMed] [Google Scholar]
  11. Langer A, Rogowski W (2009), Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res 9, 115. [CrossRef] [PubMed] [Google Scholar]
  12. Roohi SA, Barritault D (2019), ReGeneraTing Agents (RGTA(R)): A new option for healing and improving treatment outcomes for traumatic and burn injuries of the hand. Clin Case Rep 7, 619–625. [PubMed] [Google Scholar]
  13. salariés, C.N.d.l.a.m.d.t., Améliorer la qualité du système de santé et maîtriser les dépenses: propositions de l'Assurance Maladie pour 2014. 2014: France. p. 80–85. [Google Scholar]
  14. Saliba MJ Jr (2001), Heparin in the treatment of burns: a review 27, 349–358. [Google Scholar]
  15. Singer AJ, Tassiopoulos A, Kirsner RS (2017), Evaluation and management of lower-extremity ulcers. N Engl J Med 377, 1559–1567. [Google Scholar]
  16. Tong M, Tuk B, Hekking IM, Pleumeekers MM, Boldewijn MB, Hovius SE, van Neck JW (2011), Heparan sulfate glycosaminoglycan mimetic improves pressure ulcer healing in a rat model of cutaneous ischemia-reperfusion injury, Wound Repair Regen 19, 505–514. [CrossRef] [PubMed] [Google Scholar]
  17. World Medical (2013), World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191–2194. [CrossRef] [PubMed] [Google Scholar]
  18. Yamauchi H, Desgranges P, Lecerf L, Papy D, Tournaire MC, Moczar M, Loisance D, Barritault D (2000), New agents for the treatment of infarcted myocardium. FASEB J 14, 2133–2134. [CrossRef] [PubMed] [Google Scholar]
  19. Zelen CM, Serena TE, Gould L, Le L, Carter MJ, Keller J, Li WW (2016), Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J 13, 272–282. [CrossRef] [PubMed] [Google Scholar]